Oral contraceptives in systemic lupus erythematosus: Side-effects and influence on the activity of SLE

Scandinavian Journal of Rheumatology

Volumn 20, Issue 6, 1991, Pages 427-433

  Julkunen, H A ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Contraceptives; Lupus erythematosus; Oral; Side effects; Systemic

Indexed keywords

ANTIBODY; AZATHIOPRINE; CORTICOSTEROID; ETHINYLESTRADIOL; GESTAGEN; LIVER ENZYME; LUPUS ANTICOAGULANT; LYNESTRENOL; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTHRITIS; ARTICLE; DEEP VEIN THROMBOSIS; DISEASE ACTIVITY; DRUG TOLERANCE; FEMALE; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MIGRAINE; MORBIDITY; NEPHRITIS; PLASMAPHERESIS; PRIORITY JOURNAL; RASH; SYSTEMIC LUPUS ERYTHEMATOSUS;

BIOLOGY; BLEEDING; BLOOD COAGULATION EFFECTS; CARBOHYDRATE METABOLIC EFFECTS; CONTRACEPTION; CONTRACEPTIVE AGENTS; CONTRACEPTIVE AGENTS, ESTROGEN; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVE AGENTS, PROGESTIN; CONTRACEPTIVE METHODS; DEVELOPED COUNTRIES; DISEASES; ECONOMIC FACTORS; EMBOLISM; ETHINYL ESTRADIOL; EUROPE; FAMILY PLANNING; GESTODENE; HEMATOLOGICAL EFFECTS; HEMIC SYSTEM; LEVONORGESTREL; LIPID METABOLIC EFFECTS; LIPIDS; LITERATURE REVIEW; MARKETING; METABOLIC EFFECTS; METRORRHAGIA; NORTHERN EUROPE; ORAL CONTRACEPTIVES; ORAL CONTRACEPTIVES, COMBINED; PHYSIOLOGY; PRICING; PULMONARY EMBOLISM; SIGNS AND SYMPTOMS; SYSTEMIC LUPUS ERYTHEMATOSUS; UNITED KINGDOM; VASCULAR DISEASES;

ADOLESCENT; ADULT; CONTRACEPTIVES, ORAL, COMBINED; ESTROGENS; FEMALE; HUMAN; LUPUS ERYTHEMATOSUS, SYSTEMIC; RETROSPECTIVE STUDIES; RISK FACTORS; SUPPORT, NON-U.S. GOV'T; THROMBOPHLEBITIS; TIME FACTORS;

EID: 0026348120     PISSN: 03009742     EISSN: None     Source Type: Journal    
DOI: 10.3109/03009749109096822     Document Type: Article

References (29)

1. Systemic lupus erythematosus, clinical aspects and treatment
2. Systemic lupus erythematosus and pregnancy
3. Sex hormone modulation of autoimmunity in NZB/NZW mice
4. Systemic lupus erythematosus exacerbated by oral contraceptives
5. Oral contraceptives and exacerbations of lupus erythematosus
6. Oral contraceptive therapy and systemic lupus erythematosus
7. Lupus 6rythemateux dissemine induit par estrogenes
8. Oral contraceptives and systemic lupus erythematosus
9. Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus
10. Lupus, pregnancy, and neonatal lupus
11. Contraception with progestagens in systemic lupus erythematosus
12. The risk of pelvic inflammatory disease in women using intra-uterine contraceptive devices as compared to non-users
13. Criteria for the classification of systemic lupus erythematosus
14. Oral contraceptives, rheumatic disease and autoantibodies
15. Rheumatic disease, abnormal serology and oral contraceptives
16. Oral contraceptives and cardiovascular disease: a critique of the epidemiological studies
17. An immune mechanism in thrombosis
18. Complications of oral contraceptives and antiphospholipid antibodies
19. Antibodies to cardiolipin and vascular complications in women taking oral contraceptives, (letter)
20. Anticardiolipin antibodies : detection by radioimmuoassay and association with thrombosis in systemic lupus erythematosus
21. A comparative study of the effect of oral contraceptives and cigarette smoking on platelet adhesiveness
22. Lupus-like anticoagulants, modulation of the protein C pathway and thrombosis
23. Hypercoagulability
24. Fibrinolytic response and oral contraceptive associated thromboembolism
25. Prekallikrein inhibition associated with lupus anticoagulant: a mechanism of thrombosis
26. “Lupus” anticoagulant and thrombosis, possible role of inhibition of prostacyclin formation
27. Estrogen-containing oral contraceptives decrease prostacyclin production
28. Lupus pregnancy. Case-control prospective study demonstrating absence of lupus exacerbation during or after pregnancy
29. Prospective study of pregnancy in systemic lupus erythematosus. Results of a multidisciplinary approach